Compare POLA & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POLA | SNOA |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 6.1M |
| IPO Year | 2016 | 2007 |
| Metric | POLA | SNOA |
|---|---|---|
| Price | $1.87 | $3.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.5K | ★ 26.0K |
| Earning Date | 11-19-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,326,000.00 | ★ $16,937,000.00 |
| Revenue This Year | N/A | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.02 |
| 52 Week Low | $1.53 | $1.75 |
| 52 Week High | $5.75 | $6.92 |
| Indicator | POLA | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 60.01 |
| Support Level | $1.80 | $3.53 |
| Resistance Level | $1.90 | $3.89 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 51.71 | 82.03 |
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.